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ABSTRACT
Resistance to cisplatin is a major challenge in the current cancer therapy. In 
order to explore new therapeutic strategies to cisplatin resistance, we evaluated, 
in a model of lung cancer (H1299 and H460 cell lines), the nature of the pathways 
leading to cell death. We observed that H1299 displayed a natural resistance to 
cisplatin due to an inability to trigger an apoptotic response that correlates with 
the induction of autophagy. However, pharmacological and genetic approaches 
showed how autophagy was a mechanism associated to cell death rather than to 
resistance. Indeed, pro-autophagic stimuli such as mTOR or Akt inhibition mediate 
cell death in both cell lines to a similar extent. We next evaluated the response to 
a novel platinum compound, monoplatin, able to promote cell death in an exclusive 
autophagy-dependent manner. In this case, no differences were observed between 
both cell lines. Furthermore, in response to monoplatin, two molecular hallmarks 
of cisplatin response (p53 and MAPKs) were not implicated, indicating the ability 
of this pro-autophagic compound to overcome cisplatin resistance. In summary, 
our data highlight how induction of autophagy could be used in cisplatin resistant 
tumours and an alternative treatment for p53 mutated patient in a synthetic lethally 
approach.
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INTRODUCTION
Cisplatin (CDDP) is one of the most widely used 
drugs in cancer therapy. [1] Its mechanism of action has 
been deeply investigated, being the DNA molecules the 
main target of this drug. [2, 3] Since early 90’s, it is known 
that apoptosis is the main mechanism by which CDDP 
exerts its cytotoxic effect [4] (For an excellent review, 
see ref. [5]). Nonetheless, resistance to this drug is still 
a major challenge in cancer therapy due to its wide use 
in the treatment of different types of tumours as well as 
its use in combination with other therapies. [1] Therefore, 
the search of new therapeutic alternatives to solve this 
problem will have an impact in the daily clinical practice. 
In this regard, novel molecules based on platinum are 
currently developed and, some of them, under clinical 
investigation like satraplatin, which is known to promote 
apoptosis to execute its therapeutic effect. [6] Furthermore, 
it has been proposed the use of novel targets for CDDP, 
like mitochondrial DNA, to overcome CDDP resistance 
rendering compounds like Platin-M which is able to 
promote an apoptotic response. [7]
Autophagy is the main mechanism for recycling 
cellular components. The most commonly studied type of 
autophagy is macroautophagy and there is already a vast 
knowledge about its molecular machinery (For a review, 
see ref. [8]). Recently, a growing body of evidences is 
implicating autophagy in cancer and its therapy. [9] There 
are several ways of how autophagy is related to cancer 
therapy. On the one hand, compounds able to trigger this 
biological response are considered novel and promising 
therapeutic approaches, being the mTOR inhibitors the 
best example (For a review, see ref. [10]). On the other 
hand, there are numerous examples of how autophagy is 
related to a resistant response as in the case 5-Fluorouracil, 
Doxorrubicin or ionizing radiation among others. [11–13] 
Even, in response to non DNA-damaging agents like Tyr-
kinase inhibitors (vg. Sorafenib), it has been observed 
the induction of autophagy, [14, 15] indicating the broad 
implication of this process in cancer therapy. In this sense, 
it is noteworthy how compounds able to block autophagy 
are considered therapeutic agents, especially in combination 
with DNA damaging agents, as in the case of chloroquine, 
but with side effects that should be considered in future 
therapies. [16] In summary, the role of autophagy in cancer 
therapy seems to be dual, with implications either in 
sensitivity and in resistance depending on the system and 
the therapeutic agent used. [17, 18]
In this context, we decided to study the basis of 
CDDP resistance in an experimental model of lung cancer. 
Our data indicate that resistance to CDDP is due to the lack 
of a functional apoptotic response. However, this resistance 
correlates with the appearance of autophagy, which seems 
to be a mechanism of cell death poorly triggered by CDDP. 
Interestingly, in response of pro-autophagic compounds 
such as mTOR or Akt inhibitors, no differences were 
detected between cell lines. Indeed, a novel platinum-
based compound monoplatin (MonoPt), which specifically 
promotes autophagy, was able to kill CDDP-resistant 
and sensitive cells in a similar fashion. This effect was 
independent of key players of the cellular response to CDDP 
such as p53 or MAPKs. Therefore, our results suggest that 
a synthetic lethality approach based on autophagy could 
open a new therapeutic window for tumours with a deficient 
response to apoptotic stimuli like CDDP.
RESULTS
Resistance to CDDP correlates with lack of 
apoptosis
To gain further insight into the basis of CDDP 
resistance in lung cancer we used H1299 and H460 cells. 
First, we performed a dose-response assay to CDDP 
in both cell lines. As expected, H1299 showed a great 
resistance by crystal violet method as well as by MTT 
(Figure 1A and 1B), in agreement with previous reports 
[19]. Considering that apoptosis is the main mechanism 
for cell death associated to CDDP we evaluated it by 
different methods in both experimental models. While 
H460 cells displayed a consistent induction of apoptosis 
by means of flow cytometry assays (Figure 1C and 1D), 
western blotting and caspase enzymatic activity (Figure 1E 
and 1F), no effect was observed in H1299 cells (Figures 
1C, 1D, 1E, 1F). In the case of H460, no activation on 
caspase 8 was observed (data not shown) thus leading 
us to conclude that apoptosis was triggered through the 
extrinsic pathway. To fully prove our observations, we 
challenged a pan-caspase inhibitor like Q-VD-OPh 
(Q-VD). [20] Q-VD was able to promote a decrease in 
the apoptotic response in H460 cells that correlates with 
an increase in their viability. Interestingly, the same 
compound did not modify the response in H1299 (Figures 
1G and 1H). Furthermore, another DNA-damaging agent 
such as ionizing radiation, known to promote apoptosis, 
was challenged in this experimental system showing again 
a correlation between resistance and lack of apoptosis 
(Supplementary Figure S1). In summary, this set of 
experiments demonstrate that the lack of apoptosis is a 
key mechanism in the resistance observed in H1299 cells.
To fully understand CDDP resistance associated 
to H1299 cells we decided to analyse several anti- and 
pro-apoptotic proteins. As it is shown (Figure 2A), 
among the anti-apoptotic, Bcl-2 family proteins, Bcl-xL 
and Bcl-w showed a slight upregulation in H1299 cells 
while a marked downregulation was observed for Bcl-2. 
In the case of pro-apototic, BH3-only proteins, Noxa and 
Bax showed a marked downmodulation in H1299 cells, 
in agreement with a previous report that connects these 
proteins to CDDP response. [21] Indeed, the use of a 
BH3-mimetic compound such as ABT263, [22] showed 
no effect onto H460 cells, while in H1299, it was able to 
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promote a discrete effect onto the apoptotic response with 
almost no effect on viability (Figures 2B and 2C). These 
last data suggest that a deregulated pattern in pro- and 
anti-apoptotic proteins could be a mechanism to partially 
explain the resistant phenotype observed in H1299 cells. 
However, it should coexist with other mechanisms to fully 
explain the acute resistance of these cells.
H1299 cells undergo autophagy in response to 
CDDP
A growing body of evidences support that autophagy 
is a putative mechanism of resistance to CDDP. [23–25] 
Therefore, we decided to challenge this hypothesis in 
our experimental model by evaluating lipidation of LC3 
and degradation of p62/SQTSM1 following standard 
procedures. [26] As it is shown, H1299 cells showed an 
increase in the lipidated form of LC3 (LC3-II) as well 
as a decrease of p62/SQSTM1 in response to CDDP, 
which were not observed in H460 cells (Figure 3A). In 
fact, transfection of GFP-LC3 in H1299 renders a pattern 
consistent with the induction of autophagy (Supplementary 
Figure 2A). To fully support the role of autophagy in 
CDDP resistance, H1299 and H460 cells were incubated 
in the presence of a known autophagy inhibitor, 
3-methyladenine (3MA), [27] and viability in response to 
CDDP was evaluated. As expected (Figure 3B), inhibition 
of autophagy by 3MA did not modify the viability of H460 
Figure 1: CDDP triggers cell death through the apoptotic pathway on H460 cells but not on H1299 cells. Cells were 
treated for 48 h at the indicated concentrations and survival and viability were assessed by crystal violet A. or MTT B. respectively.  
C. Cells were treated with 12.5 μM CDDP for 36 h and stained with Annexin V-FITC/Propidium Iodide for cytometric assay. D. Results 
from 3 independent experiments conducted as in (C). E. Cells were treated with CDDP at indicated concentrations for 36 h and protein 
extracts were blotted with the indicated antibodies F. Cells were treated with 12.5 μM CDDP for 24 h and caspase 3/7 activity was 
evaluated. G. Cells were treated and processed as in (C) in the presence or absence of 10 μM Q-VD caspase inhibitor and plotted as 
in (D). H. Survival upon treatment with CDDP, at the indicated concentrations, in the presence or absence of 10 μM Q-VD caspase 
inhibitor measured by crystal violet 48 h after co-treatment.
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Figure 2: Pro- and anti- apoptotic protein expression pattern in H1299 and H460 cells. A. Presence of Bcl-2 superfamily 
members and BH3-only proteins was evaluated by western blot after 36 h of CDDP treatment. B. Cells were treated with CDDP in the 
presence or absence of 20 nM of ABT263 and Annexin V staining was observed 36 h after by cytometry. C. Viability was evaluated in the 
same conditions as in (B) 48 h after by crystal violet method.
Figure 3: Autophagy is associated to cell-death in H1299 cells in response to CDDP. A. H460 cells were treated for 36 h and 
protein extracts were blotted with the indicated antibodies. B. and C. Cells were treated with CDDP at the indicated concentrations in the 
presence or absence of 2.5 mM 3MA. Viability was assessed by MTT. D. Extracts from H460 cells and H1299 cells infected either with 
lentivirus carrying an empty vector or shRNA against Atg5 were blotted against ATG5. E. H460 cells and H1299 cells F. were infected as 
described in D and treated with the indicated concentrations of CDDP and viability was measured by MTT.
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cells. Surprisingly, in H1299 cells we observed an increase 
in the resistance (Figure 3C). These data prompted us to 
consider that autophagy was a mechanism to explain the 
low cell death observed in H1299 cells. Next, we used a 
genetic approach to fully establish the role of autophagy 
in CDDP resistance. To this end, Atg5 gene, which is key 
player in the progression of autophagy, [8] was knocked-
down by using shRNA. After achieving an effective 
abrogation of ATG5 at the protein level in both cell lines 
(Figure 3D), viability was evaluated, showing almost no 
effect in H460 cells, while an increase in viability was 
observed in H1299 cells (Figures 3E and 3F) correlating 
with a lack of autophagy (Supplementary Figure S2B).
Therefore, this set of experiments allows us to 
conclude that autophagy is not mediating the observed 
resistant phenotype. Furthermore, it suggests that 
autophagy is a plausible way to explain the cell death 
poorly triggered by CDDP in H1299 cells.
H1299 do not display resistance to compounds 
that promote autophagy
In light of our previous results, we considered 
the possibility of exploiting autophagy as a therapeutic 
mechanism in our experimental model of CDDP-resistant 
cells. A growing body of evidences is supporting the 
PI3K-Akt-mTOR axis as a potent therapy target in several 
types of cancers including lung cancer. [28] Hence, we 
challenged a potent promoter of autophagy such as 
rapamycin. As expected, both cell lines showed a marked 
induction of autophagy (Figure 4A) and a similar grade 
of toxicity in response to rapamicyn (Figure 4B). Next, 
treatment with the Akt inhibitor MK2206, known to 
promote autophagic cell death [29] was also evaluated. As 
it is shown in Figure 4C and 4D, both cell lines showed 
the same behaviour in terms of autophagy, Akt inhibition 
and viability upon MK2206 treatment. Therefore, these 
results indicate that autophagy induction is effective 
in both models to a similar extent and no resistance to 
autophagy-prone drugs was observed in this experimental 
system. In light of these findings we took advantage of 
the availability of a novel platinum derivate, monoplatin 
(MonoPt) able to promote specifically autophagic cell 
death. [30] Then, cells were exposed to MonoPt and 
viability was evaluated. As it is shown, H1299 and H460 
cells showed similar sensitivity to this platinum compound 
as judged by crystal violet method (Figure 5A) or by 
MTT (Figure 5B). Next, we confirmed the induction of 
autophagy (Figure 5C and Supplementary Figure 3A) 
as well as the lack of apoptosis induction (Figure 5D). 
In this case, blockade of autophagy promotes a resistant 
phenotype in both cell systems by using either 3MA 
(Figures 5E and 5F) as well as the interference of Atg5 
(Figures 5G and 5H), correlating with an alteration in the 
onset of autophagy (Supplementary Figures 3B and 3C).
In summary, our data demonstrate how autophagy 
can be used as a novel synthetic lethally approach to 
overcome natural resistance to CDDP when apoptotic 
response is impaired.
MonoPt-triggered autophagy is p53- and 
MAPKs independent
In an attempt to fully validate our strategy, the use 
of an autophagy-provoking compound in CDDP-resistant 
cells, we challenged the role of two major determinants 
of CDDP resistance such as p53 and MAPKs signalling 
axis [31].
The role of the tumour suppressor p53 in CDDP 
resistance has been well established for more than 
20 years. [32] In fact, in our experimental model, a 
strict correlation exists between lack of functional p53 
and resistance. Therefore, to study the role of p53 in 
MonoPt-associated autophagy, we took advantage of the 
availability of the experimental model of HCT116 cells 
with both p53 alleles disrupted [33] (Figure 6A). Next, 
cells were exposed to CDDP or MonoPt and viability 
was evaluated. As expected, p53-null cells showed a 
clear resistance compared to p53-wt cells in response to 
CDDP (Figure 6B). However, in the case of MonoPt, the 
differences were undetectable (Figure 6C). Furthermore, 
apoptosis was analysed, showing a nice correlation 
with sensitivity to CDDP, while for MonoPt no effect 
was observed as judged by caspase 3/7 activity (Figure 
6D). However, a marked induction of autophagy was 
observed in both experimental systems (Figure 6E). This 
set of experiments indicates that autophagy associated to 
MonoPt is independent of p53 activity, and could be a 
therapeutic alternative for patients with alterations in this 
tumour suppressor.
Next, MAPKs were challenged in response to 
MonoPt. Among the several members of this family, we 
decided to focus onto p38 and ERK1/2, which have been 
shown to be implicated in the response to CDDP. [34, 
35] As it is shown in Figure 7A, H460 cells displayed 
a marked increase in the activation of p38 MAPK in 
response to MonoPt, while in the case of H1299, it almost 
remains unaffected, with exactly the same pattern than 
in response to CDDP (data not shown and ref. [19]). 
Therefore, to fully evaluate the role of this particular 
MAPK we used a specific inhibitor for all p38MAPK 
isoforms, such as BIRB796, [36] suggesting no role for 
this signalling pathway in response to MonoPt (Figure 
7B). Regarding to ERK1/2, both cell lines showed a 
marked increase in the activation of this MAPK (Figure 
7A). However, inhibition of this signalling pathway by 
means of U0126, [37] only promotes resistance in H460, 
correlating with the blockade of autophagy, with no effect 
onto H1299 (Figures 7B, and 7D). In summary, this set of 
experiments demonstrates a lack of implication for p38 
MAPK in the response to MonoPt and suggests that the 
effect of ERK1/2 seems to be cell-type specific, indicating 
that this signalling pathway can be excluded as universal 
mediator for the therapeutic effect of MonoPt.
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DISCUSSION
Several conclusions can be drawn from the present 
study. First, the lack of apoptosis is the main mechanism, 
at least in our experimental model of lung cancer, for 
CDDP resistance. This observation is inferred from 
the data obtained in H1299 cells, which were unable to 
trigger an apoptotic response. In this sense, promotion of 
apoptosis is a possible way to induce chemosensitivity 
in CDDP-based therapy. To this end, several approaches 
have been considered such as the effective abrogation of 
anti-apoptotic proteins, [38] the use of natural compounds, 
[39] modulation of specific genes [40] or the use of BH3 
mimetic compounds [41, 42] among others. However, 
these interesting possibilities do not seem to be applicable 
to our current model of H1299 cells, in which, for example 
the use of ABT263, a BH3 mimetic, only induces a slight 
increase in the apoptotic response of this cell line towards 
CDDP with an almost undetectable shift in its sensitivity. 
Therefore, our data suggest that, at least in some cases 
(vg. H1299 cells), promotion of apoptosis is not a real 
therapeutic alternative.
Second, regarding to autophagy, it has been 
considered as a mechanism of resistance to CDDP in 
several pathologies including ovarian and lung cancer. [24, 
43, 44] However, in addition to the data presented here, 
there are other evidences that do not support this idea as a 
general mechanism. For example, in several experimental 
models, this conclusion is based on a mere correlation 
rather than in a cause-effect demonstration (For example, 
refs. [45–49]). In some reports, the effect due to autophagic 
alterations seems to be discreet in terms of viability [43, 
45, 50, 51] or the evidences presented are based only on 
the use of chemical inhibitors such as chloroquine or 3MA 
(vg. refs. [52–55]) which have been reported to also act 
trough an autophagy-independent mechanism even in 
response to CDDP. [56, 57] In addition, other evidences 
connecting autophagy and CDDP resistance are based onto 
resistant cell lines obtained by co-culturing [47, 50] or 
even CDDP plus other drugs. [58] In fact, in this context of 
acquired resistance, very different from natural resistance 
like in H1299 cells, previous evidences demonstrate how 
suppression of autophagy is a mechanism of resistance, 
[59] suggesting that autophagy is a potential mechanism 
of sensitivity. Furthermore, it is noteworthy that autophagy 
has been proposed as the mechanism to induce cell death 
in response to CDDP in the absence of key apoptotic 
proteins. [60] Therefore, our data demonstrate that when 
CDDP is unable to trigger an apoptotic response -the 
natural and effective mechanism of cell death associated 
to this drug, autophagy, -probably less effective than 
apoptosis in response to CDDP- is promoting cell death, 
indicating that both process cannot coexist. [25] Thus, our 
work excludes autophagy as mechanism of resistance to 
CDDP in our model, supporting the idea of a cytotoxic 
autophagy. [18, 61]
Figure 4: Both H460 and H1299 cells are sensitive to autophagy triggered by mTOR or Akt inhibition. A. Cells were 
exposed to rapamycin for 24 h. Protein extracts were blotted with the indicated antibodies B. Cells were incubated with the indicated 
concentrations of rapamycin for 6 days. Media were replaced with fresh rapamycin every 2 days. Viability was assessed by MTT. C. Cells 
were treated with MK2206 for 24 h. Protein extracts were blotted with the indicated antibodies. D. Cells were treated with 10 μM MK2206 
for 48 h. Viability was assessed by MTT.
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Third, our data support a lack of involvement of 
classical mediators of CDDP resistance (vg p53 and 
MAPK) in the response to MonoPt. Regarding to p53, 
the data obtained in H1299 as well as in HCT116 p53−/−, 
support that this approach can also be used in mutant-p53 
tumours. This issue is especially important considering that 
alterations in p53 (mutation, inactivation, etc.) are common 
events in different types cancers (For more information, see 
http://p53.free.fr/ and http://p53.bii.a-star.edu.sg/index.php) 
and are also major determinants in the therapeutic response 
Figure 5: Lack of resistance to MonoPt in H1299 cells. Cells were treated with indicated concentrations of MonoPt. Survival and 
viability were assessed by crystal violet A. and by MTT B. respectively. C. Cells were treated with MonoPt for 36 h and protein extracts were 
blotted against LC3 and p62. D. Cells were treated as indicated for 24 h and caspases 3 and 7 activity was evaluated. H460 E. and H1299 cells 
F. were co-treated with 2.5 mM 3MA at the indicated concentrations of MonoPt. Viability was assessed by MTT. G. ATG5-knock-down and 
control H460 and H1299 H. cells were treated with the indicated concentrations of MonoPt. Viability was measured by MTT.
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to CDDP. [32, 62, 63] Indeed, other determinants of chemo-
resistance linked to p53 such as MNK2 and wee-1 [64, 65] 
could be overcome by MonoPt due to its p53 independent 
mechanism. Regarding to p38 MAPK, previous report did 
not detect any activation of p38 MAPK by MonoPt, [30] 
however our data show how p38 MAPK is activated with 
the same pattern than in response to CDDP (Data not shown 
and ref. [19]). In this regard, it is notorious that p38 MAPK, 
which has been proposed as a key mediator in the response 
to CDDP [19, 35, 66] is not likely to be extrapolated to 
MonoPt, probably due to the different cell death mechanism 
triggered. Finally, regarding to ERK1/2, previous report 
Figure 6: Autophagy triggered by MonoPt is p53 independent. A. Cells were blotted to check p53 knock-out. Cells were 
treated at the indicated concentrations of either CDDP B. or MonoPt C. for 48 h. Survival was measured by crystal violet. D. Cells were 
treated with the indicated concentrations of either CDDP or MonoPt for 24 h. Caspase3/7 enzymatic activity was measured. E. Cells 
were treated with 25 μM of either CDDP or MonoPt for 24 h. Protein extracts were blotted with the indicated antibodies.
Figure 7: Role of MAPKs in the response to MonoPt. A. Cells were treated with the indicated concentrations of MonoPt for  
8 h. Protein extracts were blotted with the indicated antibodies. B. and C. Cells were treated with 4.69 μM MonoPt either alone or in the 
presence of 10 μM BIRB796 or 10 μM U0126. Viability was measured by MTT. D. Cells were treated with 25 μM MonoPt in the presence 
or absence of 10 μM U0126 for 24 hours. Protein extracts were blotted with the indicated antibodies.
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considered this MAPK as determinant of MonoPt toxicity 
[30] in the same sense as in CDDP response. [34, 43] In 
our experimental model, we found out that autophagy 
triggered by MonoPt can be either ERK1/2 dependent and 
independent as it is shown by the use of U0126 in both cell 
lines, indicating that ERK1/2 are not universal mediators 
of MonoPt-associated autophagy. Therefore, the definitive 
role of ERK1/2 in MonoPt response needs to be more 
deeply investigated.
Finally, a synthetic lethality approach based on the 
balance of autophagy/apoptosis should be considered 
as a novel way to overcome chemoresistance to CDDP 
(Figure 8). Synthetic lethality means that a combination of 
mutations in two genes leads to cell death, while one single 
mutation has no effect (For a review, see ref. [67]). This 
genetic principle can be extrapolated to several biological 
processes including cancer therapy. [68, 69] It is noteworthy, 
that previous works proposed synthetic lethality approaches 
for platinum-based therapy by using PARP-inhibitors, [70] 
or the use of ATR inhibitors in XRCC1 deficient cells. [71] 
The idea of autophagy as an agent in cancer therapy has 
been previously considered (For a review, see ref. [72]). 
But, what is more recent, is the concept of autophagy in 
synthetic lethality approaches for cancer therapy as in the 
case of renal cell carcinoma (For a review, see ref. [73]). 
In this sense, our report is the first evidence showing the 
potential role of a synthetic lethality approach based on the 
use of two biological processes (autophagy and apoptosis) 
for platinum-based therapy. This possibility is extremely 
interesting in tumours with a compromised apoptotic 
response, one of the main mechanisms of resistance to 
CDDP, showing a new alternative to the classical approach 
based on potentiation of CDDP-associated apoptosis. [74, 
75]. Furthermore, considering the tumour heterogeneity 
known to be implicated in the therapeutic response, [76] 
our approach could overcome this problem as in the case of 
clones with different status in key molecules as p53.
In summary, we present a novel therapeutic 
approach to target those tumours in which the apoptotic 
capability of a given stimulus (CDDP) is not triggered 
(vg p53-mutant). In this context, the use of compounds 
with a high potential to trigger autophagy (vg. MonoPt) 
Figure 8: Proposed model for the use of autophagy in cisplatin-resistant tumours.
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could induce cell death independently of major molecular 
determinants (vg p53, MAPKs). Whether our proposed 
mechanism could apply to other types of tumours, the 
putative implications in cancer therapy, as well as the 
role of the different components of this synthetic lethally 
approach, needs to be further investigated.
MATERIALS AND METHODS
Cell lines and cell culture
H460 and H1299 (non-small-cell lung carcinoma 
(NSCLC)) cells were purchased from ATCC and 
maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (D6171, Sigma Aldrich), supplemented with 
10% foetal bovine serum (F7524, Sigma Aldrich), plus 
antibiotics (Penicillin, Streptomycin and Amphotericin B) 
(A5955, Sigma Aldrich) and L-Glutamine (G7513, Sigma 
Aldrich) at 37ºC in a 5% CO2 atmosphere.
Antibodies and chemicals
Antibodies against LC3 were purchased from Sigma 
Aldrich (L8918). Antibodies against p62/SQSTM1 (sc-
28359), total p38α (sc-535), total ERK2 (sc-154), p53 
(sc-126) and α-Tubulin (sc-32293) are from Santa Cruz 
Biotechnologies. Antibodies against phosphorylated 
forms of p38 MAPK (#9215) and ERK1/2 (#4377) and 
against ATG5 (#2630), Caspase 3 (#9662) and Caspase 9 
(#9502) were purchased from Cell Signaling Technologies 
(CST). Antibodies against Bcl2-family members were 
the following ones: Bcl-2 (sc-7382, Santa Cruz), Bcl-
xL (#2762, CST) and Bcl-w (sc-130701, Santa Cruz). 
Antobodies used against BH3-only proteins were the 
following: Noxa (IMG-349A, Imgenex) and Bax (sc-493, 
Santa Cruz).
Pan-p38 inhibitor BIRB796 (also known as 
Doramapimod) was purchased from Cayman Chemicals 
(10640). MEK1/2 inhibitor U0126 (S1102), Akt inhibitor 
MK2206 (S1078) and BH3 mimetic molecule ABT-263 
(S1001) were from Selleckchem. Rapamycin (553210) and 
3-methyladenine (3MA) (189490) were purchased from 
Calbiochem/Merck–Millipore and pan-caspase inhibitor 
Q-VD was from R&D Systems (OPH001-01M). These 
chemicals were diluted in DMSO and stored at –20ºC 
(–80ºC for U0126 and MK2206) until they were used.
Cis-diamminedichloroplatinum (II) (cisplatin, 
CDDP) was purchased from Sigma Aldrich (P4394) and 
diluted in bidistilled water, aliquoted and stored at –20ºC 
until used.
Monoplatin (MonoPt) was synthesized under an 
inert atmosphere of dry oxygen-free nitrogen using 
standard Schlenk techniques. Solvents were dried from 
the appropriate drying agents before use, [77] and 
stored in presence of 4 Å molecular sieves. FAB+ mass 
spectrometry measurements were obtained in a Thermo 
MAT95XP mass spectrophotometer with magnetic sector. 
1H NMR spectra were recorded at 298K on Varian Gemini 
FT-400 and Inova FT-500 spectrometers. Chemical 
shifts (ppm) are relative to tetramethylsilane (1H NMR). 
Coupling constants (J) are in Hertz. 1H−1H COSY 
spectra: standard pulse sequence with an acquisition 
time of 0.214s, pulse width of 10 ms, relaxation delay 
of 1s, 16 scans, 512 increments. In the NMR analysis, 
s, d, t, m, and bs denote singlet, doublet, triplet, 
multiplet, and broad signal, respectively. For the molar 
conductimetry measurements, the ΛM values are given 
in S·cm2·mol−1 and were obtained at room temperature 
for 10-3 M solutions of the corresponding complexes in 
CH3CN, using a CRISON 522 conductimeter equipped 
with a CRISON 5292 platinum conductivity cell. [78] 
The ligand N-(tert-butoxycarbonyl)-L-methionine-N’-
8-quinolylamide was prepared according to literature 
procedures. [79]. Although the synthesis of the MonoPt 
complex was described previously, [30] different attempts 
to follow the reported procedure in our laboratory have 
resulted in a mixture of products, containing a platinum 
complex with an unprotected -NH2 group due, probably, 
to the Boc cleavage. In order to avoid these problems, and 
thereby the formation of by-products, the reaction was 
carried out at 60 ºC in the presence of two equivalents of 
K2CO3, resulting in a new dimeric platinum complex (Di-
Pt) that was obtained as pure in good yield. In a second 
step, the hydrolysis of Di-Pt with HCl leads to MonoPt 
as a pure compound. Synthesis of Di-Pt is explained in 
Supplementary Figure 4. [79] MonoPt was diluted in 
DMSO and stored at -20ºC as previously described. [30]
Survival and viability assays
An initial population of 2·104 cells/well was seeded 
in 24-well plates. 24 hours after, media were discarded and 
replaced by media containing either drugs, inhibitors or 
both of them at the concentrations indicated in each case. 
After treatment (48 hours unless otherwise is indicated), 
survival or viability were assessed either by crystal violet 
method or by MTT respectively. For crystal violet, cells 
were washed with PBS and incubated with crystal violet 
reactant (C3886, Sigma Aldrich) (10 mg/ml in a distilled 
water-0.5% glutaraldehyde solution) for 20 min at room 
temperature in mild rocking. The dye was washed in 
running water and colorant was recovered with 10% 
acetic acid and transferred to transparent 96-well plates 
for optical density evaluation at 595 nm. MTT assays 
were carried out as follows: MTT reactant (Thiazolyl 
Blue Tetrazolium Bromide, M2128, Sigma Aldrich), 
at 5mg/ml in a PBS solution, was added to the cells in 
a 1:10 ratio (MTT solution:culture medium) and left for 
incubation during 1 h at 37ºC. Then, media were discarded 
and formazan crystals adhered to the plate bottom were 
recovered with DMSO and transferred to a transparent 96-
well plate for optical density evaluation at 570 nm.
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Apoptosis assays
For caspase activation assays, cells were plated at a 
density of 104 cells/well in opaque 96-well plates 24 hours 
prior to treatment. 24 hours after treatment, activation of 
effector caspases 3 and 7 was evaluated with Promega’s 
CaspaseGlo kit (G8090) following manufacturer’s 
instructions. Resulting mixtures were quantified after 30 
minutes of incubation at room temperature in a Beckton 
Dickinson BD 3096 luminometer.
For Annexin V/Propidium Iodide citometry assays, 
cells were seeded in 60-mm culture plates for a final 
population of 70% confluence. After treatments, cells 
were collected by trypsinization at the indicated times, 
pelleted and washed twice with ice-cold PBS. A kit form 
Immunostep (ANXVF-200T, BB10X-50ML and “PI”) was 
used for FITC-AnnexinV and Propidium Iodide staining 
following manufacturer’s instructions. Experiments were 
checked for fluorescence in both green and red channels 
in a MACSQuant Analyzer 10 cytometer from MACS/
Miltenyi Biotec. Dot plot corresponds to data obtained 
from a representative experiment out of three. Grouped 
column charts are the average of, at least, 3 independent 
experiments.
Irradiation
Cells were irradiated in a Clinac Low Energy 600C 
linear electron accelerator from Varian by the technical 
staff of the University Hospital Complex of Albacete 
according to the indications described elsewhere. [80] For 
dose-response assays, 3·103 cells/well were seeded in 24-
well plates 24 hours prior to irradiation. Culture medium 
was replaced 24 hours after IR and refreshed every 2 days 
until the end of the experiment (6 days). Viability was 
evaluated by the crystal violet method.
Western blotting
Western blot assays were performed following 
standard procedures. [26, 80] Briefly, cells were collected 
in lysis buffer (25 mM HEPES pH 7.5, 0.3 M NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.1% SDS, 
0.5% deoxycholic acid, 20 mM β-glycerophosphate) plus 
protease and phosphatase inhibitors (2 μg/ml leupeptin, 2 
μg/ml aprotinin, 1 mM PMSF and 0.1 mM Na3VO4) by 
using 40 μg of total cell lysates. α-Tubulin was used as a 
loading controls. Images show a representative experiment 
out of 3 with nearly identical results.
shRNA knock-down assays, lentiviral 
production and infections
Plasmids codifying for short hairpin RNA (shRNA) 
against Atg5 were purchased from Sigma-Aldrich 
(SHCLNG-NM_004849). Prior to the experiments, the 
best performing shRNA clone was selected as judged by 
western blot against endogenous ATG5.
Lentiviral production and infections were as follows: 
HEK 293T cells were cotransfected with pSAXS (helper 
plasmid) and pVSV-G (envelope plasmid) lentiviral 
vectors along with either pLKO-puro-shATG5 or pLKO-
puro empty vector (SHC001, Sigma-Aldrich) plasmids. 
Host cells were infected by adding packaging cells’ media 
in the presence of 4 μg/ml polybrene from Sigma-Aldrich 
(H9268). 48 hours after infection cells were exposed to 
puromycin (ant-pr-1, Invivogene): 2 μg/ml for H460 and 3 
μg/ml for H1299 cells, for at least 3 days before any assay. 
Infected cells were routinely maintained at the appropriate 
concentrations of puromycin.
Tranfections
H1299 cells were transfected with pEX-GFP-
hLC3wt or pEX-GFP-hLC3ΔG120 previously described, 
by using Lipofectamine LTX from Invitrogene 
(#15338500) following manufacturer’s instructions. 
48 hours later, cells were selected by using G-418 from 
Sigma-Aldrich (A1720) at 800 μg/ml for at least 10 
days. Then, selected pools were treated and analysed as 
indicated in Zeiss LSM-710 confocal microscope. Images 
were acquired and processed using Zen 2009 Light Edition 
software. Images show a representative fields out of 8. The 
scale bars represent 25 μm.
Data analysis
Results are represented as mean ± SEM (Standard 
Error of the Mean) of, at least, three independent 
experiments performed in triplicate. Statistical analysis 
was performed using the Prism 5.00 software (GraphPad) 
and Office Excel 2013 (Microsoft). Significance was 
determined using a t-test. The statistical significance of 
differences is indicated in Figures by asterisks as follows:
*⇒ p < 0.05; **⇒ p < 0.01; and ***⇒ p < 0.001.
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